On October 24, 2025, AbbVie terminated its Phase 1 clinical trial of ABBV-303 for advanced solid tumors, a move that may affect its oncology pipeline and competitive positioning. This development is notable as it comes just days before AbbVie is scheduled to report Q3 earnings on October 31, 2025. Despite this, AbbVie stock closed at $228.03 (+0.02%) on October 27, 2025, with after-hours trading at $229.00 (+0.43%), indicating a muted immediate market reaction. Investors are likely awaiting further commentary from management on the pipeline and strategic direction during the upcoming earnings call.